- Seer (SEER, Financial) launches its new Proteograph® Product Suite to revolutionize deep proteomic studies.
- The suite doubles throughput to over 1,000 samples weekly and reduces analysis costs by 60%.
- Commercial availability for the new Proteograph Product Suite begins on June 1, 2025.
Seer, Inc. (SEER), a leader in deep proteomics, announced the debut of its enhanced Proteograph® Product Suite at ASMS 2025. This suite features the Proteograph ONE Assay and SP200 Automation Instrument, setting a new standard in mass spectrometry-based proteomic analysis.
The newly introduced workflow enables a groundbreaking weekly throughput of over 1,000 samples per instrument, effectively doubling the processing capability from previous iterations. This enhancement comes with a significant cost reduction, slashing per-sample analysis costs by approximately 60% compared to its 2021 release.
One of the key advancements of the new Proteograph workflow is the automation feature that achieves run times of under 5 hours for 80-sample batches. This efficiency not only reduces operator-induced variability but also enhances the reproducibility of results, critical for large-scale biomarker discovery and disease research.
By identifying up to 10 times more proteins than traditional mass spectrometry workflows, Seer’s new Proteograph Product Suite opens new avenues for research in various fields, including neurodegenerative diseases and cancer biomarker discovery. The suite will be available for commercial purchase starting June 1, 2025, both directly and via Seer's Technology Access Center.
